Cleveland BioLabs, Inc. (CBLI) stock is higher by 6.94% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With CBLI Stock Today?
Cleveland BioLabs, Inc. (CBLI) stock is trading at $2.31 as of 11:49 AM on Monday, Oct 19, a gain of $0.03, or 1.41% from the previous closing price of $2.28. The stock has traded between $2.30 and $2.50 so far today. Volume today is 128,347 compared to average volume of 148,506.
To screen for more stocks like Cleveland BioLabs, Inc. click here.
More About Cleveland BioLabs, Inc.
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Click Here to get the full Stock Score Report on Cleveland BioLabs, Inc. (CBLI) Stock.
